Last SFr.81.10 CHF
Change Today +0.25 / 0.31%
Volume 3.5M
NOVN On Other Exchanges
SIX Swiss Ex
New York
SIX Swiss Ex
As of 11:45 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-reg (NOVN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/4/14 - SFr.81.70
52 Week Low
10/10/13 - SFr.66.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVARTIS AG-REG (NOVN)

novartis ag-reg (NOVN) Details

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines. Its Consumer Health division offers over-the-counter medicines comprising readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. The company distributes its OTC products through various channels, such as food, drug, and mass retail outlets, as well as pharmacies; and Animal Health products directly and through wholesalers of veterinary products. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

135,000 Employees
Last Reported Date: 07/17/14
Founded in 1895

novartis ag-reg (NOVN) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.3.1M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: SFr.747.1K
President of Institutes for Biomedical Resear...
Total Annual Compensation: $1.9M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: $2.0M
Division Head of Animal Health and Member of ...
Total Annual Compensation: SFr.1.4M
Compensation as of Fiscal Year 2013.

novartis ag-reg (NOVN) Key Developments

Sandoz Receives Approval in Latin America for AirFluSal Forspiro

Vectura Group plc confirmed that its partner Sandoz, has been granted marketing authorization by the Mexican Health Authority (COFEPRIS) for AirFlusal Forspiro, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The approval in Mexico is the first in Latin America and follows the marketing authorizations in a total of eight European countries as well as in South Korea. Four European countries have already launched AirFluSal Forspiro in addition to the launch in May 2014 in South Korea. Mexico has approved Airflusal Forspiro in the 50-100 µg, 50-250 µg and 50-500 µg dosage forms and the product will be branded IrFlosol Forspiro. AirFluSal Forspiro offers the proven combination of salmeterol (a long-acting inhaled ß2-agonist) and fluticasone propionate (an inhaled corticosteroid) in an innovative new device. The product's safety, efficacy and equivalence have been proven in multiple clinical trials. Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal Forspiro by Aeropharm GmbH in Rudolstadt, Germany, Sandoz's global respiratory Center of Excellence. The innovative and intuitive-to-use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.

Pharmstandard to Start Local Production of Novartis's Oncology Drug Tasigna

Pharmstandard announced that it has concluded an agreement with Novartis for the localisation of the production of the latter's oncology drug Tasigna. The drug will be manufactured at the company's facility in Ufa, Bashkiria. The source adds that Pharmstandard will also promote and sell Tasigna in Russia. Tasigna is indicated for the treatment of Philadelphia Chromosome positive chronic myeloid leukaemia in adults.

Novartis Provides Drug Candidate Compounds to TB Alliance

Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD). Under the terms of agreement, NITD will fully transfer its TB research and development program to TB Alliance, which will take financial and operational responsibility for continued research, development, approval and distribution of compounds in the portfolio. Included is a novel class of drugs called indolcarboxamides that are active against drug sensitive and multi-resistant strains of TB. One of these preclinical compounds NITD304, blocks MmpL3, a protein essential for the TB bacterium's survival.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVN:VX SFr.81.10 CHF +0.25

NOVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $101.55 USD +0.76
Merck & Co Inc $59.08 USD -0.405
Roche Holding AG SFr.265.80 CHF +0.30
Sanofi €80.59 EUR +1.31
Procter & Gamble Co/The $83.03 USD +0.2201
View Industry Companies

Industry Analysis


Industry Average

Valuation NOVN Industry Range
Price/Earnings 23.8x
Price/Sales 3.6x
Price/Book 3.1x
Price/Cash Flow 24.6x
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at